Previous 10 | Next 10 |
Amarin ([[AMRN]] +0.3%) has received positive recommendation from the Committee for Medicinal Products for Human Use ((CHMP)) for its marketing application for icosapent ethyl for the reduction of risk of cardiovascular events in patients at high cardiovascular risk, under the brand name...
Positive opinion is based on extensive clinical study results, including results of the REDUCE-IT ® cardiovascular outcomes study European Commission decision on the Marketing Authorisation Application expected in April 2021 DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 29, 2...
VASCEPA® (Icosapent Ethyl) Receives Further Inclusions in Guidelines from International Medical Societies for its Role in Reducing the Risk of Cardiovascular Events Canada NewsWire Vascepa included in Consensus Statement by the American Association of Clinical...
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), announced today an expansion of the scope of its VASCEPA ® (icosapent ethyl) cardiovascular (CV) risk reduction patent infringement lawsuit against Hikma Pharmaceuticals P...
The Chinese Society of Cardiology has included Amarin's (AMRN) icosapent ethyl in its updated Guidelines for Primary Prevention of Cardiovascular Diseases for 2021.The guideline authors include “icosapent ethyl 2 grams twice a day (as studied in REDUCE-IT) as a treatment consideration ...
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Chinese Society of Cardiology (CSC) has included icosapent ethyl in its updated Guidelines for Primary Prevention of Cardiovascular Diseases for 2021 as pub...
Today, we revisit a 'battleground' stock that is one of the more volatile names in my portfolio, Amarin. There has been a lot of news flow on this name since we last took an in-depth look at in July of last year. We update our investment thesis to account for recent happenings aro...
Despite a global pandemic, the S&P 500 gained 16% in 2020 while the tech-heavy Nasdaq grew by nearly 44%. Those are stellar returns historically, but not every stock delivered for investors. Amarin (NASDAQ: AMRN) and Carnival Corp. (NYSE: CCL) (NYSE: CU...
Amarin Corporation PLC (AMRN) 39th Annual JPMorgan Virtual Healthcare Conference January 12, 2021 2:00 PM ET Company Participants John Thero - Amarin's president and chief executive officer Conference Call Participants Jessica Fye - JPMorgan Presentation Jessica Fye Great. Good afternoon, eve...
Amarin (AMRN) provides business update, including preliminary FY 2020 revenue results. FY20 total net revenue is expected to be ~$610M. The company expects European regulatory approval for Vascepa in early 2021, with CHMP opinion expected in late January or February 2021.EMA approval expected...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...